Physician profile

Devan Marar

Cardiovascular Disease · San Francisco, CA

NPI 1114152717

$1,460.62

in general payments reported to CMS, 2019-2025

15 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Esperion Therapeutics, INC. $518.00 2020
Amgen INC. $199.19 2019-2020
Janssen Pharmaceuticals, INC $159.06 2019-2020
Bayer Healthcare Pharmaceuticals INC. $125.00 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $95.21 2019
Boehringer Ingelheim Pharmaceuticals, INC. $55.43 2019
Irhythm Technologies, INC. $48.57 2019-2020
Cathworks, INC. $46.94 2020
E.R. Squibb & Sons, L.L.C. $45.83 2021
Pfizer INC. $36.58 2019-2020
Astrazeneca Pharmaceuticals Lp $36.50 2019-2020
Bardy Diagnostics, INC. $35.72 2021-2022
Heartflow, INC. $23.88 2019
Astellas Pharma US INC $22.39 2019
Sanofi-Aventis U.S. LLC $12.32 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Devan Marar

$1,460.62

in general payments reported 2019-2025

Years
2019-2022
Top company
Esperion Therapeutics, INC.

https://glasscript.com/doctor/186777/devan-marar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.